A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine.

Estephan, Lila; Liu, Luke Tzu-Chi; Lien, Chia En; Smith, Emily R; Gurwith, Marc; Chen, Robert T

Estephan, Lila; Liu, Luke Tzu-Chi; Lien, Chia En; Smith, Emily R; Gurwith, Marc; Chen, Robert T.

Afiliação

Estephan L; Medigen Vaccine Biologics Corp., Taipei, Taiwan.
Liu LT; Medigen Vaccine Biologics Corp., Taipei, Taiwan.
Lien CE; Medigen Vaccine Biologics Corp., Taipei, Taiwan; Institute of Public Health, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Smith ER; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA. Electronic address: bc-coordinator@taskforce.org.
Gurwith M; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.
Chen RT; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.

Vaccine ; 41(15): 2615-2629, 2023 04 06.

Article em En | MEDLINE | ID: mdl-36925422

Assuntos

COVID-19; Vacinas Virais; Adulto; Adolescente; Humanos; Idoso; COVID-19/prevenção & controle; SARS-CoV-2; ChAdOx1 nCoV-19; Anticorpos Neutralizantes; Adjuvantes Imunológicos; Vacinas Sintéticas; Medição de Risco; Anticorpos Antivirais; Imunogenicidade da Vacina

Palavras-chave

Benefit/Risk; COVID-19; Protein; SARS-CoV-2; Safety; Vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Vacinas Virais / COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Humans Idioma: En Revista: Vaccine Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Taiwan

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google